HealthFDA Requests New Trial for Cancer Drug, Compass Stock Drops $104M
Compass announced that the FDA has recommended conducting a new trial demonstrating a survival benefit before the company can file a biologics license application for tovecimig, a treatment for previously treated advanced biliary tract cancer. This announcement caused Compass's stock to plunge, wiping out $104 million in value, with Wedbush predicting a further 19% decline.
Asianet Newsable·21h ago

